These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36374339)

  • 1. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.
    Liu Z; Jiang S; Gu J; Liu H; Song G; Cao X
    Ann Hematol; 2023 Jan; 102(1):167-174. PubMed ID: 36374339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
    Liang Z; Ren H; Cen X; Li Y; Wang L; Ou J; Dong Y; Yin Y; Wang W; Liu W; Wang Q; Qiu Z; Wang M; Xu W; Sun Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):225-30. PubMed ID: 24666489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
    Xu JY; Yan WW; Fan HS; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2338-2344. PubMed ID: 35970791
    [No Abstract]   [Full Text] [Related]  

  • 8. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
    Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
    Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.
    Riva E; Duarte PJ; Valcárcel B; Remaggi G; Murrieta I; Corzo A; Del Carpio D; Peña C; Vásquez J; Bove V; Teixeira L; Fleury-Perini G; Yantorno S; Samánez C; Lopresti S; Altamirano M; Villela L; Ruiz-Arguelles GJ; Ruiz-Delgado GJ; Montaño E; Verri V; Zamora Pérez E; Pérez Jacobo F; Idrobo H; Martínez-Cordero H; Beltran BE; Ramírez J; Castillo JJ; Malpica Castillo LE
    JCO Glob Oncol; 2022 Aug; 8():e2100380. PubMed ID: 35939775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
    Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
    Leblond V; Morel P; Dilhuidy MS; Leleu X; Soussain C; Leprête S; Dreyfus B; Dartigeas C; Mahé B; Anglaret B; Pégourié B; Besson C; Aurran T; Vekhoff A; Tournilhac O; Banos A; Oya H; Lejeune J; Ouzegdouh M; Chevret S;
    Leuk Lymphoma; 2017 Nov; 58(11):2615-2623. PubMed ID: 28395585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High plasma D-dimer level is a poor prognostic factor for patients with waldenström macroglobulinemia.
    Cao X; Kong YL; Wang L; Zhu HY; Liang JH; Xia Y; Fan L; Shi WY; Liu H; Li JY; Xu W
    Leuk Lymphoma; 2020 May; 61(5):1140-1146. PubMed ID: 31928271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Short-Term Efficacy and Safety Profile of Generic Bortezomib in the Treatment of Multiple Myeloma].
    Liao RQ; Lin XJ; Li XL; Ni X; Luo WF; Zhao P; Chen J; Wei J; Zou XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):137-144. PubMed ID: 33554810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 16. A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients.
    Byun JM; Shin J; Kim SA; Park H; Lee J; Shin DY; Hong J; Lee JO; Bang SM; Kim I; Yoon SS; Koh Y
    Cancer Res Treat; 2024 Apr; 56(2):675-680. PubMed ID: 37752793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
    Gu WW; Wang JS; Mu K; Ren G
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
    Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
    Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
    Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.